Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Frederick Dominick Sancilio
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 0
- Beta
- 0.29
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.08
Financials
Revenue
$0.00-100.0%Net Income
$-529.9KEBITDA
$-1.18MFree Cash Flow
$-707.9KEPS (diluted)
$-0.00Shares Outstanding (diluted)
277.75M+39578.3%Operating Expenses
$1.18MCash & Debt
$5.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-4.42M | $-0.03 |
| 2024 | $136.2K | $-4.42M | $-0.04 |
| 2023 | $840.5K | $-4.71M | $-0.05 |
| 2022 | $0.00 | $-12.25M | $-0.32 |
| 2021 | $0.00 | $-9.66M | $-0.30 |
| 2020 | $884.8K | $-3.44M | $-0.30 |
| 2019 | $773.8K | $-754.0K | $-0.09 |
| 2018 | $0.00 | $-148.0K | $-0.24 |
| 2017 | $0.00 | $-51.8K | $-0.08 |
| 2016 | $0.00 | $-56.0K | $-0.24 |
| 2015 | $0.00 | $-170.8K | $-0.15 |
| 2014 | $0.00 | $-134.0K | $-0.19 |
| 2013 | $0.00 | $-93.1K | $-0.16 |
| 2012 | $0.00 | $-91.0K | $-1.18 |
Valuation
LOBEFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
142+372.22%Social Signal Score
Mentions (6)
- Newsaccessnewswire.com·21d ago·Negative
Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit ● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16 ● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses ● Lobe to ex
View source ↗ - Newsnewsfilecorp.com·22d ago·Neutral
Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in the upcoming 3 rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel.
View source ↗ - Newsaccessnewswire.com·35d ago·Negative
… SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce closing of the second tranche of its previously announced non-brokered private placement offering of common shares in the capital of the Company ("Common Shares"…
View source ↗ - Newsaccessnewswire.com·38d ago·Negative
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd.
View source ↗ - Newsaccessnewswire.com·47d ago·Negative
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd.
View source ↗ - Newsaccessnewswire.com·55d ago·Negative
Lobe Sciences Ltd. Announces Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd.
View source ↗
Earnings
Mon, Dec 28(in 3 months)
Estimates and results for LOBEF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in LOBEF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.